News for Ligand Pharmaceuticals Incorporated (LGND)

JUPITER, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated ( LGND) today announced that it will report second quarter 2025 financial

JUPITER, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated ( LGND) today announced that its partner Pelthos Therapeutics Inc. ( Amer

ZELSUVMI is now commercially available via prescription through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmacies

U.S. stocks were higher, with the Dow Jones index gaining around 0.1% on Wednesday. Shares of Verona Pharma plc VRNA rose sharply during Wednesday's session af...

The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025

Pelthos plans to launch ZELSUVMI™ for the treatment of Molluscum contagiosum infections in July 2025

**media[651594]**

**media[625382]**

JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated ( LGND) today announced that its senior management team will participate i

JUPITER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated ( LGND) today announced that it will report first quarter 2025 financial

**media[604227]**

U.S. stocks traded mostly lower midway through trading, with the Dow Jones index falling more than 450 points on Thursday. The Dow traded down 1.20% to 39,191....

U.S. stocks traded mixed this morning, with the Dow Jones index falling more than 1% on Thursday. Following the market opening Thursday, the Dow traded down 1....

Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos' ZELSUVMIâ„¢

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and Channel Therapeutics Corporation (NYSE:CHRO) on Thursday signed a definitive merger agreement to combine Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc. (collectively Pelthos) with CHRO Merger Sub Inc., a wholly owned subsidiary of Channel. The merger will be supported by $50 million in capital raised from a group of strategic investors led by Murchinson. Under the merger agreement, Channel will acquire 100% of Pe

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

**media[555300]**

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2024 Earnings Call Transcript February 27, 2025Ligand Pharmaceuticals Incorporated misses on earnings expectations.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ETCompany ParticipantsMelanie Herman - Senior...